V
Val R. Adams
Researcher at University of Kentucky
Publications - 59
Citations - 1695
Val R. Adams is an academic researcher from University of Kentucky. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 22, co-authored 57 publications receiving 1486 citations. Previous affiliations of Val R. Adams include Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Doxorubicin and Paclitaxel-Loaded Lipid-Based Nanoparticles Overcome Multidrug Resistance by Inhibiting P-Glycoprotein and Depleting ATP
Xiaowei Dong,Cynthia Mattingly,Michael T. Tseng,Moo J. Cho,Yang Liu,Val R. Adams,Russell J. Mumper +6 more
TL;DR: Enhanced uptake and prolonged retention of doxorubicin were observed with nanoparticle-based formulations in P-gp-overexpressing cells, and injection of pegylated paclitaxel nanoparticles showed marked anticancer efficacy in nude mice bearing resistant NCI/ADR-RES tumors versus all control groups.
Journal ArticleDOI
Sunitinib Malate for the Treatment of Metastatic Renal Cell Carcinoma and Gastrointestinal Stromal Tumors
Val R. Adams,Markos Leggas +1 more
TL;DR: Sunitinib is a multiple tyrosine kinase receptor inhibitor approved for the treatment of mRCC and GIST and has anti-tumor activity in patients with breast cancer, neuroendocrine tumors, and non-small cell lung cancer.
Journal ArticleDOI
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects
Aimee K. Bence,Eric B. Anderson,Maqbool A. Halepota,Michael Doukas,Phillip A. DeSimone,George A. Davis,Deborah A. Smith,Kevin M. Koch,Andrew G. Stead,Steve Mangum,Carolyn J. Bowen,Neil L. Spector,Showchien Hsieh,Val R. Adams +13 more
TL;DR: Single and multiple oral doses ofGW572016 were well tolerated in healthy subjects, and resulted in dose-related systemic exposure of GW572016, which was similar between treatment and placebo groups.
Journal ArticleDOI
Development of New Lipid-Based Paclitaxel Nanoparticles Using Sequential Simplex Optimization
TL;DR: Cytotoxicity studies in MDA-MB-231 cancer cells showed that both nanoparticles have similar anticancer activities compared to Taxol, and Interestingly, PX BTM nanocapsules could be lyophilized without cryoprotectants and rapidly rehydrated with a complete retention of original physicochemical properties, in vitro release properties, and cytotoxicity profile.
Journal ArticleDOI
PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses
Patrick J. Medina,Val R. Adams +1 more
TL;DR: A basic understanding of the role of PD‐1 in modulating the immune system and their use in the cancer treatment is provided, along with pharmacokinetic and pharmacodynamic data and cost considerations.